Camrelizumab is a humanized high-affinity IgG4-kappa anti-PD-1 monoclonal antibody that has demonstrated efficacy and safety in patients with advanced ESCC [8, 9]. Here, PDCD1 is linked to esophageal squamous cell carcinoma.